Autolus Therapeutics (AUTL) Return on Capital Employed (2020 - 2025)
Autolus Therapeutics posted quarterly Return on Capital Employed of 49.01% for Q4 2025, down 1657.0% year-on-year from 3.15% in Q4 2024, and down 8.84% on a QoQ basis from 45.03% in Q3 2025.
Autolus Therapeutics (AUTL) has 6 years of Return on Capital Employed data on file, last reported at 49.01% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 1657.0% year-over-year to 49.01%; the trailing twelve-month figure through Dec 2025 stood at 49.01% (down 1657.0% YoY), and the FY2025 full-year result was 44.17%, up 241.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 49.01%, down from 45.03% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 23.17% in Q2 2024 and bottomed at 14154.58% in Q3 2021.
- The 5-year median for Return on Capital Employed is 42.81% (2025), against an average of 2556.64%.
- The widest annual swing landed in 2021, when Return on Capital Employed slumped 1410173 bps; it then jumped 1410035 bps in 2022.
- A 5-year view of Return on Capital Employed shows it stood at 12239.32% in 2021, then soared by 100 bps to 37.57% in 2022, then sank by 38 bps to 51.94% in 2023, then surged by 38 bps to 32.43% in 2024, then slumped by 51 bps to 49.01% in 2025.
- The last three Return on Capital Employed figures came in at 49.01% (Q4 2025), 45.03% (Q3 2025), and 40.6% (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 21.10% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 10.19% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 20.34% |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn | -49.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -49.01% |
| Sep 30, 2025 | -45.03% |
| Jun 30, 2025 | -40.60% |
| Mar 31, 2025 | -38.39% |
| Dec 31, 2024 | -32.43% |
| Sep 30, 2024 | -27.77% |
| Jun 30, 2024 | -23.17% |
| Mar 31, 2024 | -30.17% |
| Dec 31, 2023 | -51.94% |
| Sep 30, 2023 | -35.31% |
| Jun 30, 2023 | -31.98% |
| Mar 31, 2023 | -29.21% |
| Dec 31, 2022 | -37.57% |
| Sep 30, 2022 | -54.23% |
| Jun 30, 2022 | -13,007.73% |
| Mar 31, 2022 | -11,090.38% |
| Dec 31, 2021 | -12,239.32% |
| Sep 30, 2021 | -14,154.58% |
| Jun 30, 2021 | -55.17% |
| Mar 31, 2021 | -58.92% |
| Dec 31, 2020 | -61.12% |
| Sep 30, 2020 | -52.85% |
| Jun 30, 2020 | -45.47% |
| Mar 31, 2020 | -52.10% |